CROs Getting Govt. Support To Help Countermeasure Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
BARDA’s Clinical Studies Network aims to reduce the number of countermeasure development failures.
You may also be interested in...
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
GAIN has encouraged FDA to be flexible on data requirements for antibiotics, according to sponsors.
Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
BARDA Signs Biodefense Contracts With GSK And Soligenix
Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.